Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03333616
Title Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

germ cell cancer

penile cancer

urinary bladder cancer

adrenocortical carcinoma

urinary system cancer

prostate cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California, San Diego Moores Cancer Center Recruiting La Jolla California 92093 United States Details
Winship Cancer Institute, Emory University Recruiting Atlanta Georgia 30322 United States Details
Beth Israel Deaconess Medical Center Recruiting Boston Massachusetts 02115 United States Details
Dana-Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
Ohio State University Comprehensive Cancer Center Recruiting Columbus Ohio 43210 United States Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field